StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SKR-R.BK$7.50+0.00%
Fair $7.50+0.0%

SKR-R.BK

Sikarin Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$7.50

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $7.50Fund rank 38/100 · Data gapFallback financials|
SA 52/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $903.2M · quality 81.3/100

Data gap 38/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 81/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

52/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · SKR-R.BKLocal privado en este navegador · Sikarin Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$15.2B

P/E

22.7x

↑

EV/EBITDA

9.6x

↓

ROE

9.6%

↑

Gross Margin

30.1%

↓

Debt/Equity

0.08

↓
52-Week Range$8
$7$8

TradingView lightweight chart

SKR-R.BK price, volumen y niveles de valoración

Último $7.000Periodo -33.3%
Fair value: $7.500

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+2.1%

FCF CAGR

+6.9%

FCF margin

18.5%

FCF / Net income

1.49x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $6.05B · net income $751.8M · FCF $1.12B

2022-FY → 2025-FY

Gross margin

30.1%-5.8% pts

Operating margin

15.5%-7.2% pts

Net margin

12.4%-5.4% pts

FCF margin

18.5%+2.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$6.05B$6.05B$6.06B$5.82B$5.67B
Net Income$751.8M$751.8M$663.6M$891.1M$1.01B
EBITDA$1.58B$1.58B$1.43B$1.66B$1.78B
EPS0.370.370.320.430.49
Gross Margin30.1%30.1%29.1%34.4%35.9%
Operating Margin15.5%15.5%13.8%19.4%22.7%
Net Margin12.4%12.4%11.0%15.3%17.8%
Balance Sheet
Debt/Equity0.080.080.110.100.14
Current Ratio3.493.49———
Cash Flow
Free Cash Flow$1.12B$1.12B$903.2M$578.6M$914.4M
Returns
ROE9.6%9.6%8.7%12.1%14.8%
Valuation
P/E22.7322.7329.4324.1928.06
EV/EBITDA9.599.5913.6913.1415.93
P/B1.961.962.532.914.15
Growth & Yield
Revenue Growth-0.2%-0.2%4.1%2.6%—
EPS Growth15.6%15.6%-25.6%-12.2%—
Dividend Yield3.6%3.6%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

21.6%

exigente

EPS terminal req.

$0.67

Spread vs growth

-6.0%

5Y implied EPS CAGR

16.8%

exigente

EPS terminal req.

$0.81

Spread vs growth

-1.2%

10Y implied EPS CAGR

13.4%

razonable

EPS terminal req.

$1.30

Spread vs growth

2.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -6.9%

Total return

-6.9%

Start / end P/E

24.4x → 18.9x

EPS bridge

0.32 → 0.37

Residual

-3.5%

EPS growth+15.6%
Multiple rerating-22.6%
Dividend+3.6%
Residual / FX / buybacks / cross-term-3.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.